Caldwell Sutter Capital’s GSK GSK Stock Holding History

Caldwell Sutter Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$183K	Sell	3,497 -60	-2%	-$3.17K	0.07%	233
2026 Q1	$196K	Buy	3,557 +9	+0.3%	+$488	0.08%	223
2025 Q4	$174K	Hold	3,548	–	–	0.07%	228
2025 Q3	$153K	Sell	3,548 -235	-6%	-$9.18K	0.07%	241
2025 Q2	$145K	Sell	3,783 -86	-2%	-$3.29K	0.07%	237
2025 Q1	$150K	Sell	3,869 -173	-4%	-$6.33K	0.07%	230
2024 Q4	$137K	Sell	4,042 -127	-3%	-$4.57K	0.06%	244
2024 Q3	$170K	Sell	4,169 -26	-0.6%	-$1.06K	0.08%	220
2024 Q2	$162K	Sell	4,195 -1,159	-22%	-$48.8K	0.08%	222
2024 Q1	$230K	Sell	5,354 -938	-15%	-$38.7K	0.11%	178
2023 Q4	$233K	Sell	6,292 -757	-11%	-$27.2K	0.12%	166
2023 Q3	$256K	Sell	7,049 -12	-0.2%	-$426	0.14%	146
2023 Q2	$252K	Buy	7,061 +3,436	+95%	+$123K	0.13%	153
2023 Q1	$129K	Buy	+3,625	New	+$127K	0.09%	168

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caldwell Sutter Capital's GSK Position: Q2 2026 in Review

Caldwell Sutter Capital reduced its GSK (GSK) stake by 1.7% in Q2 2026, selling an estimated $3.17K and leaving 3,497 shares worth $183K. The position accounts for 0.07% of the portfolio, ranked #233.

Caldwell Sutter Capital first reported a position in GSK in Q1 2023 and has held it in 14 quarters since. The position peaked at $256K in Q3 2023. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Caldwell Sutter Capital held 3,497 shares of GSK worth $183K as of Q2 2026.
Caldwell Sutter Capital sold 60 GSK shares in Q2 2026, an estimated $3.17K.
GSK made up 0.07% of Caldwell Sutter Capital's portfolio in Q2 2026, its #233 holding.
Caldwell Sutter Capital first reported a position in GSK in Q1 2023 and has held it in 14 quarters since.
Caldwell Sutter Capital's GSK position peaked at $256K in Q3 2023.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.